Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Receives European Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)

For security reasons, registration is required before you can use this feature.
* Indicates required field